Can estrogen excess in men cause osteoporosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Estrogen Excess in Men and Osteoporosis

Estrogen excess in men does not cause osteoporosis; rather, it is estrogen deficiency that significantly contributes to bone loss and osteoporosis in men. Evidence from multiple studies demonstrates that estrogens play a crucial role in maintaining bone health in males, and low estrogen levels are associated with increased bone turnover and accelerated bone loss.

The Role of Estrogen in Male Bone Health

Physiological Basis

  • Estrogen is produced in men through peripheral aromatization of testosterone to estradiol 1
  • Osteoblast-like cells can directly aromatize androgens into estrogens 2
  • Estrogen receptors are expressed in both osteoclasts and osteoblasts 3

Evidence Supporting Estrogen's Role in Male Bone Health

  1. Genetic Evidence: Men with mutations in the estrogen receptor alpha gene or aromatase gene (preventing estrogen action or production) develop osteopenia and unfused epiphyses 4

  2. Observational Studies:

    • In men over 65 years, there is a positive association between bone mineral density (BMD) and serum estradiol levels 2
    • Longitudinal studies show bioavailable estrogen correlates better than testosterone with both BMD gain in young men and BMD loss in elderly men 4
  3. Interventional Evidence:

    • When both testosterone and estrogen were withdrawn in elderly men, estrogen played the major role in regulating bone resorption 4
    • Both estrogen and testosterone were important in maintaining bone formation 4

Estrogen Deficiency and Osteoporosis in Men

Men with estrogen levels below the median show:

  • Higher rates of bone loss at the lumbar spine and femoral neck
  • Greater decrease in speed-of-sound measurements at the calcaneus
  • Significantly higher bone turnover markers (bone alkaline phosphatase and urinary crosslaps) 5

The ratio between estradiol and testosterone (an indirect measure of aromatase activity) increases with age and is higher in men with normal bone density than in osteoporotic men, suggesting that the ability to convert testosterone to estradiol is protective against osteoporosis 5.

Clinical Implications

Risk Factors for Osteoporosis in Men

  • Hypogonadism (leading to both testosterone and estrogen deficiency) 2
  • Androgen deprivation therapy (ADT) for prostate cancer 3
  • Aging (associated with declining testosterone and estrogen levels) 5
  • Glucocorticoid excess (predominantly from exogenous sources) 2
  • Gastrointestinal diseases causing malabsorption 2

ADT and Bone Health

ADT reduces testosterone levels, which subsequently reduces estradiol levels through decreased aromatization:

  • In population studies, low estradiol levels are more closely associated with fracture incidence than low testosterone levels 3
  • ADT is associated with accelerated bone loss and increased fracture risk 3

Treatment Considerations

For men with established osteoporosis:

  • Bisphosphonates are recommended to reduce vertebral fracture risk in men with clinically recognized osteoporosis 3
  • Zoledronic acid has shown efficacy in reducing vertebral fractures in osteoporotic men 3
  • Estrogen therapy is not currently recommended for men with osteoporosis, though research suggests potential benefits of targeted estrogen receptor modulation 2

Common Pitfalls and Caveats

  1. Diagnostic Challenges:

    • Up to 60% of men with vertebral fractures have another illness contributing to bone disease 2
    • Secondary causes of osteoporosis should always be excluded
  2. Treatment Considerations:

    • Bone density monitoring is not recommended during the 5-year pharmacologic treatment period for osteoporosis 3
    • Calcium and vitamin D supplementation may be considered alongside osteoporosis treatments, though careful dosing is needed to avoid hypercalcemia 3
  3. Research Gaps:

    • The USPSTF notes that evidence for primary prevention of osteoporosis in men is lacking, and future research is needed 3
    • The effectiveness of drug therapies in reducing fracture rates in men without previous fractures remains inadequately assessed 3

In conclusion, rather than causing osteoporosis, estrogen plays a protective role in male bone health, and it is estrogen deficiency that contributes to bone loss in men.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Estrogens and bone health in men.

Calcified tissue international, 2001

Research

Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men.

The Journal of clinical endocrinology and metabolism, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.